Fulgent Genetics (FLGT) Liabilities and Shareholders Equity (2016 - 2025)
Fulgent Genetics (FLGT) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $1.2 billion as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 0.53% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 billion through Dec 2025, down 1.67% year-over-year, with the annual reading at $1.2 billion for FY2025, 0.53% down from the prior year.
- Liabilities and Shareholders Equity hit $1.2 billion in Q4 2025 for Fulgent Genetics, roughly flat from $1.2 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q1 2022 to a low of $999.1 million in Q1 2021.
- Historically, Liabilities and Shareholders Equity has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2024.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 1018.48% in 2021 and later dropped 10.67% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $1.3 billion in 2021, then grew by 1.1% to $1.3 billion in 2022, then fell by 4.45% to $1.2 billion in 2023, then decreased by 1.24% to $1.2 billion in 2024, then fell by 0.53% to $1.2 billion in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for FLGT at $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.2 billion in Q2 2025.